The Food and Drug Administration has lately approved atezolizumab, anti-programmed death ligand 1 (PD-L1), to be used together with nanoparticle albumin-bound (nab) paclitaxel in treating patients with triple negative breast cancer (BC) expressing PD-L1. Nonetheless, immune checkpoint inhibitors (ICIs) are still challenged by the resistance and immune-related adverse effects evident in a considerable subset of treated patients without conclusive comprehension of the underlying molecular basis, biomarkers and tolerable therapeutic regimens capable of unleashing the anti-tumour immune responses. Stepping back to preclinical models is thus inevitable to address these inquiries. Herein, we comprehensively review diverse preclinical models of BC exploited in investigating ICIs underscoring their pros and cons as well as the learnt and awaited lessons to allow full exploitation of ICIs in BC therapy.

Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside / A.K. Abdel-Aziz, M.K. Saadeldin, P. D'Amico, S. Orecchioni, F. Bertolini, G. Curigliano, S. Minucci. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 122(2019 Nov), pp. 22-41. [10.1016/j.ejca.2019.08.013]

Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside

G. Curigliano
;
S. Minucci
2019

Abstract

The Food and Drug Administration has lately approved atezolizumab, anti-programmed death ligand 1 (PD-L1), to be used together with nanoparticle albumin-bound (nab) paclitaxel in treating patients with triple negative breast cancer (BC) expressing PD-L1. Nonetheless, immune checkpoint inhibitors (ICIs) are still challenged by the resistance and immune-related adverse effects evident in a considerable subset of treated patients without conclusive comprehension of the underlying molecular basis, biomarkers and tolerable therapeutic regimens capable of unleashing the anti-tumour immune responses. Stepping back to preclinical models is thus inevitable to address these inquiries. Herein, we comprehensively review diverse preclinical models of BC exploited in investigating ICIs underscoring their pros and cons as well as the learnt and awaited lessons to allow full exploitation of ICIs in BC therapy.
Breast cancer; CTLA-4; Immune checkpoint inhibitor; PD-1; PD-L1; Preclinical model; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; CTLA-4 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Humans; Immunologic Factors; Immunotherapy; Programmed Cell Death 1 Receptor; Triple Negative Breast Neoplasms; Drug Evaluation, Preclinical
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Abdel Aziz.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/824442
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact